Previous 10 | Next 10 |
2024-06-13 17:28:51 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis) Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global ...
Augtyro is the only FDA-approved treatment option for NTRK -positive tumors studied in both TKI-na ï ve and TKI-pretreated patients across solid tumors , demonstrating clinically meaningful response rates in the TRIDENT-1 trial 1 This accelerated approva...
2024-06-13 16:13:36 ET Summary Bristol-Myers Squibb Company stock has taken a big tumble in the past quarter following its sharply reduced earnings guidance, but there are still plenty of positives going for it. Better than expected revenue growth in Q1 2024, earnings reduction be...
2024-06-13 14:03:52 ET Summary Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reac...
2024-06-13 09:00:00 ET Summary The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but c...
2024-06-12 10:55:10 ET Summary Tri-Continental Corporation offers exposure to domestic equity securities with a 3.82% yield, lower than peers but higher than American common equity indices. The TY closed-end fund's shares have gained 14.81% over the past five years, underperformin...
2024-06-11 16:05:14 ET Summary Bristol-Myers Squibb is showing signs of potentially being a value trap. The stock price has fallen more than the underlying value of the company, but a price to free cash flow ratio of under 7x seems pessimistic. Technical support needs to estab...
2024-06-11 14:35:28 ET Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants Chris Boerner - Board Chair and Chief Executive Officer Conference Call Participants Chris Shibutan...
2024-06-11 08:37:32 ET Summary Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset. This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month. If it is positive, the stock should run again for ...
2024-06-11 01:15:00 ET Summary The Morningstar Wide Moat Focus Index faced challenges in May due to its equal-weighting, value stock bias and lack of mega-cap tech exposure. History may provide context for what comes next. US equities re-initiated their upward trend in May, with m...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...